What is a good Trial-to-Paid Conversion for HealthTech at Series A?
Quick Answer
A good Trial-to-Paid Conversion for HealthTech depends on your company stage. Seed-stage companies typically see different benchmarks than Series B+. Check our HealthTech benchmark data for stage-specific targets and how top-performing companies compare.
Detailed Answer
Understanding what constitutes a good Trial-to-Paid Conversion for HealthTech companies at Series A requires context about industry norms, growth expectations, and competitive positioning.
Trial-to-Paid Conversion benchmarks vary significantly by: company stage (seed vs growth vs public), business model (SaaS vs marketplace vs usage-based), market segment (SMB vs mid-market vs enterprise), and geography.
For HealthTech companies at Series A, the key is not hitting a specific number but rather tracking the trend. A Trial-to-Paid Conversion that is improving month-over-month indicates you are on the right path, even if the absolute number is below industry average.
We track Trial-to-Paid Conversion benchmarks across stages and industries in our benchmark database, updated with real company data. Use these as directional guidance, not as pass/fail criteria — every company's context is unique.
Related Questions
Resources
Ehsan Jahandarpour
AI Growth Strategist & Fractional CMO
Forbes Top 20 Growth Hacker · TEDx Speaker · 716 Academic Citations · Ex-Microsoft · CMO at FirstWave (ASX:FCT) · Forbes Communications Council